Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival ... For more information about ASCO's conflict of ...

There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.

SAN FRANCISCO -- An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.

BMS' application covers the use of PD-1 inhibitor Opdivo (nivolumab) with CTLA4 inhibitor Yervoy (ipilimumab ... mismatch repair deficient (dMMR) colorectal cancer that cannot be treated with ...